Recommendation of the President – Libtayo (cemiplimab)
On 27 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 136/2024 on the appraisal Libtayo (cemiplimab) under the drug program “Treatment of patients with cervical cancer (ICD-10: C53)”